Comprehensive Overview of Hereditary Diffuse Gastric Cancer (CDH1)

Hereditary Diffuse Gastric Cancer (HDGC) is a rare, autosomal dominant cancer predisposition syndrome characterized by an significantly elevated risk of developing diffuse-type gastric cancer and, in women, lobular breast cancer. The primary genetic driver for this condition is a germline mutation in the CDH1 gene, which encodes the protein E-cadherin.

E-cadherin is a critical cell-to-cell adhesion molecule. When the CDH1 gene is mutated, the structural integrity of the gastric epithelium is compromised, allowing malignant cells to infiltrate and spread diffusely through the stomach wall, often without forming a distinct mass (the "signet ring cell" morphology). Because of the high penetrance and aggressive nature of this condition, genetic testing and clinical surveillance are vital for at-risk individuals.

Technical Specifications: The Mechanism of CDH1

The CDH1 gene is located on chromosome 16q22.1. It functions as a classic tumor suppressor gene. In the context of HDGC, the "two-hit hypothesis" applies: an individual inherits one mutated allele (the first hit), and if the second functional allele is silenced or mutated in a gastric cell, the cell loses its ability to maintain adhesion, leading to uncontrolled proliferation and invasion.

Molecular Function

• Adhesion: E-cadherin forms the core of adherens junctions.
• Signaling: It regulates intracellular signaling pathways, including the Wnt/beta-catenin pathway.
• Loss of Function: Loss of E-cadherin leads to the "de-differentiation" of epithelial cells into a mesenchymal state, a process known as Epithelial-Mesenchymal Transition (EMT), which is a hallmark of metastatic cancer.

Clinical Indications and Testing Criteria

Genetic testing for CDH1 is not indicated for the general population. It is strictly reserved for individuals meeting specific clinical criteria established by the International Gastric Cancer Linkage Consortium (IGCLC).

When to Consider Testing

1. Multiple Cases: Two or more documented cases of gastric cancer in first- or second-degree relatives, with at least one confirmed diffuse-type gastric cancer at age < 50.
2. Early Onset: An individual with diffuse gastric cancer diagnosed before age 40.
3. Personal/Family History: An individual or family with both diffuse gastric cancer and lobular breast cancer (one diagnosed before age 50).
4. Histology: Individuals with signet ring cell carcinoma diagnosed at any age who have a family history of the disease.
5. Bilateral Lobular Breast Cancer: Women diagnosed with bilateral lobular breast cancer under age 50.

The Role of Genetic Counseling

Genetic testing must always be preceded and followed by professional genetic counseling. This ensures the patient understands the psychological implications, the potential for "variants of uncertain significance" (VUS), and the impact on family planning and insurance.

Specimen Collection and Laboratory Methodology

The diagnostic standard for identifying CDH1 mutations is Next-Generation Sequencing (NGS) of the entire coding region and exon-intron boundaries of the CDH1 gene.

Pre-Analytical Requirements

• Specimen Type: Peripheral blood (typically 5-10 mL in an EDTA tube) or oral mucosa (saliva kit).
• Storage: Samples should be kept at room temperature (if processed within 24-48 hours) or refrigerated. Avoid freezing unless specified by the lab.
• Interfering Factors:
  • Recent blood transfusions (may contaminate the DNA sample).
  • Bone marrow transplant (the patient's DNA will be replaced by the donor's).
  • Improper labeling or chain-of-custody errors.

Analytical Interpretation

Laboratories categorize results into five classes:
1. Pathogenic: Clinically actionable mutation identified.
2. Likely Pathogenic: High probability of disease causation.
3. VUS (Variant of Uncertain Significance): Insufficient data to determine clinical impact; generally not used for clinical decision-making.
4. Likely Benign: Not expected to cause disease.
5. Benign: No clinical significance.

Risks, Management, and Prophylactic Strategies

Testing positive for a pathogenic CDH1 mutation carries significant psychological and medical weight. The lifetime risk of gastric cancer in CDH1 mutation carriers is estimated at 70% for men and 56% for women.

Surveillance and Prophylactic Options

• Prophylactic Total Gastrectomy (PTG): This is the gold standard for mutation carriers. It involves the total removal of the stomach to eliminate the risk of invasive cancer. It is usually recommended between the ages of 20 and 30.
• Endoscopic Surveillance: For patients who defer surgery, high-definition white-light endoscopy with extensive, targeted biopsies (the "Cambridge Protocol") is required every 6–12 months. Note: Endoscopy often fails to detect early-stage signet ring cell carcinomas.
• Breast Cancer Surveillance: Annual breast MRI starting at age 30 is recommended for women, as they are at significantly higher risk for invasive lobular breast carcinoma.

Frequently Asked Questions (FAQ)

1. Does a negative CDH1 test mean I have no risk of gastric cancer?

No. A negative test indicates you did not inherit the specific CDH1 mutation present in your family. You still have the same risk as the general population for sporadic gastric cancer.

2. What is a "signet ring cell"?

It is a specific type of cancer cell that looks like a ring because the nucleus is pushed to the side by a large droplet of mucin. This is the hallmark of diffuse gastric cancer.

3. How accurate is the CDH1 genetic test?

Modern NGS panels are highly accurate (typically >99% for detecting sequence variants). However, they may miss large deletions or rearrangements, which might require additional testing (e.g., MLPA).

4. If I test positive, do my children need testing?

Yes. Since this is an autosomal dominant condition, each child of an affected parent has a 50% chance of inheriting the mutation. Testing for minors is generally deferred until age 18 unless early screening is clinically indicated.

5. Is there a cure for HDGC?

While there is no "cure" for the genetic mutation, Prophylactic Total Gastrectomy effectively eliminates the primary site of gastric cancer risk.

6. Can I be tested if I don’t have a family history?

Genetic testing is generally not recommended without a family history or specific clinical features, as the prevalence of CDH1 mutations in the general population is extremely low.

7. What happens if I have a VUS result?

A Variant of Uncertain Significance means the lab found a change, but they don't know if it's harmful. You should not make medical decisions (like surgery) based on a VUS. These are often reclassified over time as more data becomes available.

8. Does insurance cover CDH1 testing?

In most cases, if you meet the IGCLC clinical criteria, insurance providers cover the testing. Always obtain pre-authorization from your insurance provider prior to the blood draw.

9. How long does it take to get results?

Turnaround time for CDH1 sequencing usually ranges from 2 to 4 weeks, depending on the laboratory and the complexity of the interpretation.

10. Are there other genes associated with gastric cancer?

Yes. Other genes like CTNNA1, PALB2, BRCA2, and ATM have been associated with increased gastric cancer risk, and many modern lab panels include these as part of a "Gastric Cancer Multi-Gene Panel."

Conclusion for Patients and Clinicians

Hereditary Diffuse Gastric Cancer is a high-stakes diagnosis that requires a multidisciplinary approach. For patients, understanding that a CDH1 mutation is a roadmap for prevention—rather than a death sentence—is critical. Through prophylactic surgery and rigorous surveillance, the morbidity and mortality associated with this condition can be managed effectively. Clinicians must maintain a high index of suspicion for family history patterns, ensuring that genetic testing is offered to those who stand the most to gain from early intervention.

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Always consult with a board-certified genetic counselor or an oncology specialist regarding your personal health risks and medical decisions.